Effect of Atrial Fibrillation Burden on Long-term Risk of Thromboembolic Complications- the FinCV-4 Study
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,300
- 试验地点
- 1
- 主要终点
- Ischemic stroke or TIA (transient ischemic attack)
研究概览
简要总结
This study explores the association of symptomatic episodes of atrial fibrillation (AF) occurrence and long-term risk of thromboembolic complications in a retrospective setting.
详细描述
The study population consists of the FinCV-dataset, which includes 7660 acute cardioversions for atrial fibrillation. The electronic patient records of FinCV-study patients are reviewed to collect data on anticoagulation, number of cardioversions as well as mortality and stroke data. We seek to explore the possible association between the frequency of AF paroxysms in low stroke risk patients and the occurrence of death, stroke and major bleed as well as the net clinical benefit of anticoagulation. Data collection is performed by reviewing electronic patient records.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Oral anticoagulation
Patients with long term oral anticoagulation
干预措施: Anticoagulation Therapy (Drug)
结局指标
主要结局
Ischemic stroke or TIA (transient ischemic attack)
时间窗: From the first cardioversion through study completion, an average of 6 years
Ischemic stroke or TIA diagnosed by neurologist
Major Bleed
时间窗: From the first cardioversion through study completion, an average of 6 years
Major Bleeding complication according to ISTH (International Society on Thrombosis and Haemostasis)
Death
时间窗: From the first cardioversion through study completion, an average of 6 years
Death from any cause
次要结局
- Permanent oral anticoagulation(From the first cardioversion through study completion, an average of 6 years.)
研究者
Juhani Airaksinen
Professor
Turku University Hospital